In a research report sent to investors, Cowen analyst Boris Peaker reiterated an Outperform rating on Curis Inc. (NASDAQ:CRIS), following the news that the company has entered into an exclusive collaboration agreement with Aurigene Discovery for immuno-oncology and selected precision oncology targets. No price target was provided.

Peaker noted, “The collaboration between Curis and Aurigene provides Curis with options to exclusively license immuno-oncology and precision oncology targets. Under the agreement, Aurigene is responsible for all discovery and preclinical studies, including IND-enabling studies. Upon compound selection, Curis becomes responsible for clinical development, regulatory and commercialization efforts.”

The analyst added, “While still an early stage asset, we believe any success here will add significant value to CRIS stock.”

Curis is a biotechnology company focused on the development and commercialization of novel drug candidates for the treatment of human cancers.